Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii
- 19 July 2016
- journal article
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 121 (2) , 401-407
Abstract
The aim of this multi-hospital study was to assess the in vitro activity of doripenem and its comparators, imipenem and meropenem, using the new CLSI breakpoints against a large population of a frequently isolated nosocomial pathogen, Acinetobacter baumannii. During a 2-year period, four referral or tertiary hospitals submitted 400 isolates of A. baumannii for susceptibility testing using imipenem, meropenem, and doripenem via disk diffusion and E-test methods. A subset of 390 isolates was resistant to all three tested carbapenems. Doripenem and meropenem (MIC50, 32 μg ml-1) had comparable activity, albeit doripenem's activity was greater than imipenem (MIC50, >32 μg ml-1). A significantly higher proportion of the isolates were inhibited by doripenem than by imipenem at MIC values of 12, 16, 24 and 32 μg ml-1 (Pin vitro activity than imipenem in terms of zone breakpoints and MIC values, but its activity is comparable to meropenem. Doripenem should be considered as a therapeutic option for monotherapy or combination therapy, particularly when the therapeutic options are limited.Keywords
Funding Information
- Tehran University of Medical Sciences and Health Services (90-02-27-13796)
- Academy of Sciences for the Developing World (11-119 RG/PHA/AS_C-UNESCO FR: 3240262646)
This publication has 24 references indexed in Scilit:
- Antibiotic Resistance Profile and Distribution of Oxacillinase Genes Among Clinical Isolates of Acinetobacter baumannii in Shiraz Teaching Hospitals, 2012 - 2013Jundishapur Journal of Microbiology, 2015
- Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumoniaInternational Journal of Antimicrobial Agents, 2013
- The Rise of Carbapenem-Resistant Acinetobacter baumanniiCurrent Pharmaceutical Design, 2013
- Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II studyInternational Journal of Antimicrobial Agents, 2012
- Comparative activity of carbapenem testing (the COMPACT study) in TurkeyBMC Infectious Diseases, 2012
- Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary PracticesClinical Infectious Diseases, 2009
- Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluidJournal of Infection and Chemotherapy, 2008
- Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)Clinical Microbiology and Infection, 2005
- Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluationsJournal of Antimicrobial Chemotherapy, 2004
- Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactamThe Lancet, 1994